Skip to main content

Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease



Weakness is the primary impairment in paediatric neuromuscular diseases, impacting gait and gait-related functional activities in ambulant children affected by these rare and often degenerative diseases. Gait speed is an indicator of health and disability, yet gait is a complex, multi-faceted activity. Using the International Classification of Function, Health and Disability (ICF) model, assessment of gait and functional ambulation should consider the impairments, activity limitations and participation restrictions due to disease, and factors related to the environment and the individual person.


This narrative review involved a literature search of databases including Medline, Embase and Pubmed from 1946 to October 2019. Inclusion criteria included assessments of gait, endurance and ambulatory function in paediatric (0–18 years) neuromuscular diseases.


Fifty-two papers were identified reporting assessments of gait speed, timed function, endurance and ambulatory capacity, gait-related balance and qualitative descriptive assessments of gait function and effect of disease on gait and gait-related activities. Gait speed is an indicator of disability and children with neuromuscular disease walk slower than typically developing peers. Increasing disease severity and age were associated with slower walking in children with Duchenne muscular dystrophy and Charcot-Marie-Tooth disease. The six-minute walk test is used widely as a test of endurance and ambulatory capacity; six-minute walk distance was substantially reduced across all paediatric neuromuscular diseases. Endurance and ambulatory capacity was more limited in children with spinal muscular atrophy type 3, congenital muscular dystrophy and older boys with Duchenne muscular dystrophy. Only a few papers considered normalisation of gait parameters accounting for the effect on gait of height in heterogeneous groups of children and linear growth in longitudinal studies. Balance related to gait was considered in five papers, mainly in children with Charcot-Marie-Tooth disease. There was limited investigation of factors including distance requirements and terrain in children’s typical environments and personal factors related to self-perception of disease effect on gait and gait-related function.


Assessments of gait and functional ambulation are important considerations in documenting disease progression and treatment efficacy in the clinical setting; and in clinical trials of disease-modifying agents and physiotherapeutic interventions in paediatric neuromuscular diseases. There is a need for expert consensus on core gait and functional ambulation assessments for use in clinical and research settings.

Peer Review reports


Neuromuscular diseases (NMD) include disorders affecting the anterior horn cells, peripheral nerves, neuromuscular junction and muscles, are often progressive and exhibit a wide range of impairment and disability in affected individuals. Relatively rare, in children these diseases include spinal muscular atrophy (SMA; 1 in 10–11,000) [1], Charcot-Marie-Tooth disease (CMT; 1 in 2.5–10,000) [2] and Duchenne muscular dystrophy (DMD; 1 in 3.5–10,0000) [3]. Gait and functional ambulation are important markers of disease and disability in paediatric NMD. It has been proposed that gait velocity or self-selected walking speed is the 6th vital sign of human function and is a predictor of overall health and disability [4, 5]. Yet, human gait is a complex activity and gait speed alone does not reflect all contributing factors and influences on gait [4, 5]. Functional ambulation relates gait function and speed to mobility-related activities of daily living in a person’s own environment [6]. Thus, the assessment of gait and functional ambulation in paediatric NMD must take in to consideration the many constructs that contribute to these complex tasks, including individual impairments, the task required, and the environment in which these are performed.

Weakness is the primary impairment in NMD, often presenting in childhood and adversely affecting gait and functional ambulation. Additionally, muscle tightness, contracture, musculoskeletal deformities, poor standing balance and reduced endurance, all arising from weakness, affect functional ambulatory tasks such as standing and walking. Patterns of weakness differ depending on the NMD, some affecting more proximal muscles (e.g. DMD) and others more distal muscles (e.g. CMT). For the majority of NMD of childhood, disease is progressive leading to increasing weakness and disability across the lifespan. The degree of disability in childhood NMD is variable ranging from children who are extremely weak and unable to sit (e.g. SMA type 1) to those with milder weakness who remain ambulant, albeit with gait difficulties including foot drop, poor balance and reduced gait speed (e.g. CMT, SMA type 3 and ambulant boys with DMD).

Gait dysfunction has important implications for function in everyday life. Ambulant children with NMD, commonly report problems with walking, poor balance, frequent trips and falls, increased fatigue and difficulty keeping up with peers [7,8,9,10,11]. In this context, it is useful to consider the assessment of gait and functional ambulation in ambulant children with NMD in terms of the International Classification of Function, Health and Disability (ICF) [12] (Fig. 1). Gait speed is an indicator of impairment. However, a clinically meaningful assessment also needs to consider limitations to the child’s activities, restrictions to participation, environmental and intrinsic personal factors. Activity limitations may include difficulty walking longer distances; problems with balance may affect steadiness and safety when walking; and ambulatory performance may be affected by changes in environmental conditions, for example walking over uneven ground or up and down steps. The use of gait or mobility aids will also affect function and low walking confidence or fear of falling may restrict participation opportunities. Assessments of functional ambulation need to take into account all of these factors. There is no recognised single assessment tool of functional ambulation that encompasses all factors. However, there are several clinical assessments that collectively illustrate the effect of disease and disability on gait and function in children with NMD. The aim of this paper is to review assessments of gait and functional ambulation in paediatric NMD.

Fig. 1

Paediatric neuromuscular disease as it relates to the ICF – factors relating to gait and functional ambulation (bold)


This narrative review considered the literature relating to gait and functional ambulation in children and adolescents with neuromuscular disease. Literature was searched in Ovid Medline, Embase and PubMed from 1946 up to and including October 2019. Keywords and search terms included gait, walk*, ambul*, locomotion, functional ambul*, paed*, pediatr*, child*, adoles*, neuromuscular disease, Duchenne and Becker muscular dystrophy, Charcot-Marie-Tooth disease, peripheral neuropathy not diabetes, spinal muscular atrophy, myopathy, Pompe, myotonic dystrophy, collagen VI disorders, fascioscapulohumeral dystrophy or FSHD. Only full-text human studies in English were considered (see Supplementary material for example of search strategy). Additionally, hand searching of reference lists and conference abstracts was undertaken to ensure relevant publications were included. Exclusion criteria included studies of non-ambulant participants, primary studies of physical activity and activity monitoring that did not include assessments of gait or functional ambulation, and studies comprised primarily of adults (aged > 18 years).

Results and discussion

Studies included

Review of the literature resulted in 52 papers describing gait and functional ambulation in over eight neuromuscular diseases of childhood including CMT (15 papers), Becker and Duchenne muscular dystrophies (B/DMD) (21 papers), SMA (7 papers), congenital myotonic dystrophy (CMD) (2 papers), fascioscapulohumeral dystrophy (FSHD) (1 paper), Pompe disease (1 paper), collagen VI disorders (1 paper) and other mixed cohorts (4 papers) (Table 1). Two papers were systematic reviews of gait in CMT [18] and DMD [28]. Several papers described the same or similar cohorts, either cross-sectional and longitudinal studies [11, 16, 20, 21, 34, 35, 42] or a descriptive papers of a randomised controlled trial (RCT) [24, 25, 38, 39]. The median age of participants in the studies was 9.0 years and sample sizes ranged from 4 to 520. Some studies included adult participants and were included despite the lack of age-related sub-analysis [9, 10, 26, 36, 48,49,50,51,52, 56, 57, 60] or if there were no paediatric studies in a specific disease [55].

Table 1 Review papers including disease, author, study type, sample age and size, outcome measures and main findings

Assessments of gait and functional ambulation

Several assessments of gait and functional ambulation in paediatric NMD were identified and discussed in the literature. These included timed function tests, for example the 10 m walk and/or run test [62, 63], the six-minute walk test (6MWT) [64] and 100 m timed test [30]. Tests of dynamic balance in walking, including the balance subset of the Bruininks-Oseretsky Test, 2nd edition (BOT-2) [65] and the timed up and go (TUG) [66], were considered due to the impact of balance on gait and function. If studies of gait or functional ambulation included activity monitoring, these were reported as an adjunct to specific assessments of gait, however we did not specifically search for studies of activity monitoring alone. We also included descriptive scales or questionnaires that characterised gait-related function, including the Functional Mobility Scale (FMS) [67] and the Walk-12 scale [68].

Gait speed

For this review we focused on gait speed in terms of its clinical utility as an indicator of health and disability [4, 5]. Assessment of gait speed was diverse with a range of reported methodologies including 3-D gait analysis, electronic walkway and timed distance. Typically, gait is assessed at natural self-selected steady walking pace, however some studies reported gait speed as calculated from the 10 m walk/run, usually a fast walk or run test [27, 56]. Gait speed was described most often in studies of children with CMT (ten of fifteen papers), a reflection of the use of clinical gait analysis in preparation for orthopaedic surgery for the management of foot deformities common in CMT [11, 16, 18,19,20,21, 23,24,25,26]. Children with CMT walked more slowly than their typically developing peers and a decline in gait speed over time was evident when growth was accounted for by normalising gait speed to height or leg length [16]. Greater disability in children with CMT was reflected in slower gait speed in more severely affected children [19].

Younger boys (< 7 years) with DMD did not walk significantly slower than their typically developing peers [41, 45]. However, boys older than 8 years with DMD were significantly slower than their peers, an indicator of the relentless and degenerative muscle disease [8, 31]. The study by Doglio et al. (2011) was the only study to normalise gait speed to height when comparing boys with DMD to TD controls. Normalising gait parameters is an important consideration for boys with DMD who are typically treated with corticosteroids, of which growth retardation is a known side-effect. Therefore, steroid-treated boys with DMD tend to be smaller than their age-matched, steroid naïve and non-affected peers [69]. Normalisation to height and/or leg length is an important to factor when reporting gait speed in paediatric populations [70, 71].

Gait speed was reported in two other studies in children with CMD [53] and a mixed aged study of children and adults with late-onset Pompe disease [56]. Whilst neither study included unaffected controls, the reported gait speed for both cohorts was considerably slower than reported normative reference data [72].

Six-minute walk test

The 6MWT is a valid and reliable standardised test of physical endurance in boys with DMD [38]. A test of ambulatory capacity, the 6MWT measures distance walked in six minutes. Developed from the American Thoracic Society and FDA-approved 6MWT [64], the test has been modified for children with NMD with the addition of a safety chaser and standardised verbal encouragement [44]. The utility of the 6MWT in paediatric NMD clinical research is evident with over half of the studies included in this review reporting its use [9,10,11, 14, 16, 17, 24, 25, 29, 32,33,34,35, 37,38,39,40, 42,43,44, 50,51,52,53,54,55,56,57,58,59,60,61] (Table 1). Typical walkway distances were reported as 25 m however some studies used walkways as short as 10 m [24, 25]. This may reduce distance walked due to more frequent turns resulting in greater time spent decelerating and less time at a fast walking pace [73].

Six-minute walk distance (6MWD) is reduced in children and adolescents with NMD when compared to typically developing controls or normative reference data. In boys with DMD and children with SMA type 3 and CMT, 6MWD declines with increasing age, reflecting disease progression and increasing disability [10, 16, 34, 35, 37, 39, 40]. Normalisation of 6MWD to height or leg length, accounts for linear growth across age groups and in longitudinal studies, and is an important factor when determining the effect of disease on function [16]. Burns and colleagues (2009), demonstrated a trend to shorter 6MWD in older children [25]. In a further study over 12 months, normalisation of 6MWD accounting for growth revealed a decline in ambulatory capacity in children with CMT [16]. Genotype also affects ambulatory capacity in the 6MWT; children with milder subtypes of CMT in a large study of 520 participants, walked further than children with more severe subtypes [17]. Deterioration in ambulatory capacity over time was also affected by genotype in 80 boys with DMD [40]. Several studies have reported rates of change, either minimally clinically important difference (MCID) or minimal detectable change (MDC) for 6MWD in different NMD including DMD (MCID 26.4–31.7 m; − 53.67 change over 12 months) [37, 38], SMA (− 7.9 to − 9.7 m over 12 months) [10] and FSHD (MDC95 34.3 m) [55]. Measures of rate of change, MCID or MCD are useful for clinicians when comparing the ambulatory function of the children in their own clinical practice.

Timed function tests – 10 m walk/run

The timed 10 m walk/run is widely used to assess function in NMD and is a sensitive measure of disease progression in ambulant boys with DMD [62, 74, 75]. In clinical practice, the timed 10 m walk/run is conducted as a fast walk or run dependent on the abilities of the child. However, in the literature there were differences noted between whether the test was conducted as a timed walk [15, 41, 56, 57] or run, and earlier studies conducted the test over 30 ft or 9 m [46, 47]. Timed 10 m walk/run was most often reported in boys with DMD [27, 29, 36,37,38,39, 41,42,43, 46, 47] reflecting its common use as a predictor of disease in DMD and less frequently in studies of CMT, SMA, Pompe and Collagen VI [11, 15, 50, 52, 56, 57]. Across all NMDs, 10 m walk/run times were slower compared to controls or reported normative reference ranges. Disease progression in boys with DMD was demonstrated with several studies reporting slower speed over 10 m in boys older than 7 years [36, 39, 42].

Other assessments

Assessments of balance, endurance and alternative distance and timed tests (100 m timed walk and two-minute walk test) were reported less frequently. The balance subset of the Bruininks-Oseretsky Test of Motor Proficiency, 2nd Ed (BOT-2, NCS Pearson, Upper Saddle River, NJ, USA) is a ten-item standardised test of balance in standing and walking [65]. It is widely used in paediatric CMT having been incorporated into the disease-specific CMT Pediatric Scale (CMTPedS) [76]. Balance in children with CMT was significantly reduced when compared to age- and gender-matched controls and normative reference data [11, 13, 14]. However, over 12 months’, balance did not significantly deteriorate, indicative of the relatively slow progression of neuropathy in children with CMT [16]. Reduced balance (BOT-2) was associated with wider base of support and greater step-to-step variability in the gait of children with CMT [11].

The TUG was reported in two studies and is a valid, reliable and responsive measure of gait-related balance in children with physical disabilities [50, 59, 77, 78]. It measures the time taken to stand from a seated position, walk 3 m, turn around and return to a seated position. Dunaway and colleagues (2014) demonstrated an association between the TUG, slower 10 m walk/run time and shorter 6MWD in children with SMA type 3 [50]. In a further study comparing older children with peripheral neuropathies (PN) of mixed origin to younger boys with DMD, TUG times were longer in the children with mixed PN [59]. The authors attributed the difference between groups to the effects of distal versus proximal weakness patterns, however it may have also been due to the PN group being older and therefore likely to be more affected by their disease. Both the BOT-2 and the TUG are useful assessments of gait-related balance and inform clinical interpretation of the effects of NMD on gait and function.

Alternatives to the 6MWT were reported in two studies. Alfano and colleagues (2017) reported the development and validation of a 100 m timed test in boys with DMD as an assessment of functional ambulatory performance. Their study included the establishment of typically developing normative reference data [30]. Findings from this study indicated that performance on the 100 m timed test improved up to the age of 7 years before plateauing and declining with increasing age [30]. This finding is similar to the 10 m walk/run and the 6MWT in boys with DMD and is reflective of disease progression [36, 39, 40, 42]. A second study in children with mixed NMD, reported a two-minute walk distance (2MWD) derived from the two-minute mark of the standard 6MWT, and found a strong correlation between 2MWD and 6MWD [58]. Both the 100 m timed test and the 2MWT may offer realistic alternatives to the longer 6MWT, especially in children with behavioural and attentional problems who may find the time and testing constraints of six minutes challenging.

The 6MWT and more recently the 100 m timed test and 2MWT, are all described as tests of physical endurance in paediatric NMD and as surrogate measures of physical fatigue in DMD, SMA and CMT [9, 25, 44]. Bartels and colleagues (2019) have recently described the concept of fatigability in SMA, that is, “the inability to perform prolonged repetitive tasks during activities of daily life”, and have developed a group of endurance tests to assess fatigability [48]. The Endurance Shuttle Walk Test is a feasible test of endurance in ambulant people with SMA type 3. An externally paced walking task, the objective is to cover 10 m before each beep. The time between repeated beeps decreases, requiring an incremental increase in walking speed. This pilot study is the first report of the Endurance Shuttle Walk test and further studies are required to determine its validity, responsiveness and clinical utility in SMA and paediatric NMD.

The advent of wireless wearable activity monitors allows remote measurement of gait-related physical activity in children with NMD. Several studies have included wearable devices to measure steps and physical activity in DMD, CMD and mixed NMD [27, 32, 53, 61]. Davidson and colleagues (2015) found that boys with DMD have reduced daily step counts and reduced high activity time, with correspondingly greater inactivity compared to typically developing peers [32]. In a longitudinal study, Fowler and colleagues (2018) described physical activity levels in boys with DMD following a similar trajectory to timed tests and the 6MWT [27]. Daily step counts rose up to the age of 8 years, before plateauing and declining from the age of 10 years [27]. Children with NMD are largely inactive, spending up to 80% of their awake time in sedentary activities and on average only 2 h a day at a moderate intensity of activity [53, 61]. Whilst we assume neuromuscular weakness contributes to reduced physical activity, it is quite possible that reduced physical activity contributes further to increasing weakness. Lack of physical activity, together with disease-related weakness, is likely to impact gait and function in children with NMD.

Descriptive measures of gait

Together with quantitative measures of gait and function, descriptive scales and questionnaires are used to characterise gait and functional ambulation in paediatric NMD. Two such measures reported in this review are the Functional Mobility Scale (FMS) [67] and the Walk-12 [68] which have not been widely utilised in paediatric NMD to date.

The Functional Mobility Scale (FMS) is a clinical tool used to classify typical mobility over three distance categories – 5, 50 and 500 m in children with gait dysfunction [67]. These distances are commensurate with walking in the home (5 m), between classrooms in the school environment (50 m) and distances required in general community environments (500 m). The scale considers the level of assistance the child requires and a grading from 1 to 6 is applied; where 1 indicates the use of a wheelchair and 6 indicates fully independent walking on all surfaces and terrains, including stairs without use of a rail. One study has described functional mobility in children with CMT [16]. In this study 78% of the children reported reduced ambulatory function, across one or all distance/environment categories (score < 6) describing the functional impact of disease. Over 12 months there was little change in FMS scores, in keeping with the slow progression of CMT.

The Walk-12 is a self-reported questionnaire of perceived impact of disease on gait and gait related activities, such as running, using stairs and balance, modified and validated in adults with peripheral neuropathies [68, 79]. The tool is scored from 0 to 100%, where 0% indicates no impact and 100% indicates a high impact of disease on gait and related activities. In two studies, Walk-12 scores ranged from 12 to 25%, indicating that children with CMT perceived only mild impact of disease on gait and gait-related function [14, 22]. Interestingly, further examination of answers to individual questions indicated that CMT affected their ability to run (43%), ascend or descend stairs (41%), the speed with which they could walk (31%) and made it more effortful to walk (31%) [14]. Additionally, over 40% of the children reported moderate to severe limitations to their ability to walk longer distances in their everyday environments.

Clinical implications and future directions

Gait performance and functional ambulation are biomarkers of disease severity in paediatric NMD, providing a measure of disability. Assessment of gait and functional ambulation are important outcome measures in the toolbox of assessments for clinical research trials and in the clinical setting. With the advent of disease-modifying pharmacological treatments and uptake of physiotherapeutic exercise, younger people, including children with NMD are likely to benefit most from treatments. Therefore, it is important to utilise functional measures specific to children and adolescents to monitor disease progression and treatment efficacy.

There remains a need for further research and development of functional gait outcome measures for paediatric NMD. Limitations including the heterogeneity of the study populations and differences in assessment protocols precluded meta-analysis of these studies. ​As evidence accumulates, a more analytical systematic review may provide additional insights. The disparity of gait assessments in paediatric neuromuscular diseases also suggests that a Delphi survey would be useful in establishing expert consensus on which measures to use. Factors such as the normalization of gait parameters is important when comparing gait across age ranges and longitudinally to account for growth in children and should be standardly applied both clinically and in research. Further development and publication of paediatric normative reference datasets and MCIDs will be a valuable resource for clinicians working in neuromuscular clinics. Qualitative characterisation of gait and functional ambulation with scales or questionnaires enables clinicians to gain an understanding of the effect of disease on the day-to-day lives of children with NMD, beyond the neuromuscular outpatient clinic. The self-reported scales of functional mobility and gait-related activities require validation in paediatric NMD populations to ensure that they provide meaningful information and enable greater uptake by clinicians. Further exploration and utilization of technology for remote and wireless monitoring and measurement of walking in the typical environments of children, including home, school and the community provide greater understanding of the effect of disease on function.


This narrative review has highlighted clinical measures of gait ranging from gait speed to tests of ambulatory capacity, physical endurance and gait-related balance that can be conducted in clinical and research settings with relative ease. Consideration of environmental factors affecting function including distance requirements necessitated by school and community settings is important when understanding the effect of disease. An individual’s perception of the effect of disease on walking and everyday function are important considerations in the clinical setting. Person-centred characterization and assessment of gait dysfunction discussed in this narrative review provides a rich and holistic illustration of disability, and offers genuine outcome measures of potential therapeutic benefits on gait and functional ambulation in paediatric NMD. However, consensus is required amongst experts in paediatric neuromuscular disorders to establish a core set of gait and functional ambulatory assessments that can be used clinically and in research settings.

Availability of data and materials

All articles cited in this review are accessible through article repositories and journal websites.


  1. 1.

    Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20(1):27–32.

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Pareyson D, Saveri P, Pisciotta C. New developments in Charcot–Marie–tooth neuropathy and related diseases. Curr Opin Neurol. 2017;30(5):471–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24(6):482–91.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Fritz S, Lusardi M. White paper: "walking speed: the sixth vital sign". J Geriatr Phys Ther. 2009;32(2):2–9.

    Article  Google Scholar 

  5. 5.

    Middleton A, Fritz SL, Lusardi M. Walking speed: the functional vital sign. J Aging Phys Activ. 2015;23(2):314–22.

    Article  Google Scholar 

  6. 6.

    Lam T, Noonan VK, Eng JJ. A systematic review of functional ambulation outcome measures in spinal cord injury. Spinal Cord. 2007;46(4):246–54.

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Kennedy RA, Carroll K, Hepworth G, Paterson KL, Ryan MM, McGinley JL. Falls in paediatric Charcot-Marie-tooth disease: a 6-month prospective cohort study. Arch Dis Child. 2019;104(6):535–40.

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Gaudreault N, Gravel D, Nadeau S, Houde S, Gagnon D. Gait patterns comparison of children with Duchenne muscular dystrophy to those of control subjects considering the effect of gait velocity. Gait Posture. 2010;32(3):342–7.

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Montes J, Dunaway S, Montgomery MJ, Sproule D, Kaufmann P, De Vivo DC, et al. Fatigue leads to gait changes in spinal muscular atrophy. Muscle Nerve. 2011;43(4):485–8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Montes J, McDermott MP, Mirek E, Mazzone ES, Main M, Glanzman AM, et al. Ambulatory function in spinal muscular atrophy: age-related patterns of progression. PLoS One. 2018;13(6):e0199657.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Kennedy RA, McGinley JL, Paterson KL, Ryan MM, Carroll K. Gait and footwear in children and adolescents with Charcot-Marie-tooth disease: a cross-sectional, case-controlled study. Gait Posture. 2018;62:262–7.

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    International Classification of Functioning, Disability and Health (ICF): World Health Organisation; 2018 Available from:

    Google Scholar 

  13. 13.

    Estilow T, Glanzman AM, Burns J, Harrington A, Cornett K, Menezes MP, et al. Balance impairment in pediatric Charcot-Marie-tooth disease. Muscle Nerve. 2019;60(3):242–9.

    Article  Google Scholar 

  14. 14.

    Kennedy RA, Carroll K, Paterson KL, Ryan MM, Burns J, Rose K, et al. Physical activity of children and adolescents with Charcot-Marie-tooth neuropathies: a cross-sectional case-controlled study. PLoS One. 2019;14(6):e0209628.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Baptista CRD, Nascimento-Elias AH, Garcia B, Testa A, Domingues PC, Martinez EZ, et al. Physical function and performance measures of children and adolescents with Charcot-Marie-tooth disease. Physiother Theor Pr. 2019:1–8.

  16. 16.

    Kennedy R, Carroll K, Paterson KL, Ryan MM, McGinley JL. Deterioration in gait and functional ambulation in children and adolescents with Charcot-Marie-tooth disease over 12 months. Neuromuscul Disord. 2017;27(7):658–66.

    Article  Google Scholar 

  17. 17.

    Cornett KM, Menezes MP, Bray P, Halaki M, Shy RR, Yum SW, et al. Phenotypic variability of childhood Charcot-Marie-tooth disease. JAMA Neurology. 2016;73(6):645–51.

    Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Kennedy RA, Carroll K, McGinley JL. Gait in children and adolescents with Charcot-Marie-tooth disease: a systematic review. J Peripher Nerv Syst. 2016;21(4):317–28.

    Article  Google Scholar 

  19. 19.

    Ounpuu S, Garibay E, Solomito M, Bell K, Pierz K, Thomson J, et al. A comprehensive evaluation of the variation in ankle function during gait in children and youth with Charcot-Marie-tooth disease. Gait Posture. 2013;38(4):900–6.

    Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Ferrarin M, Lencioni T, Rabuffetti M, Moroni I, Pagliano E, Pareyson D. Changes of gait pattern in children with Charcot-Marie-tooth disease type 1A: a 18 months follow-up study. J NeuroEng Rehabil. 2013;10(1):1–11.

    Article  Google Scholar 

  21. 21.

    Ferrarin M, Bovi G, Rabuffetti M, Mazzoleni P, Montesano A, Pagliano E, et al. Gait pattern classification in children with Charcot-Marie-tooth disease type 1A. Gait Posture. 2012;35(1):131–7.

    Article  CAS  Google Scholar 

  22. 22.

    Pagliano E, Moroni I, Baranello G, Magro A, Marchi A, Bulgheroni S, et al. Outcome measures for Charcot-Marie-tooth disease: clinical and neurofunctional assessment in children. J Peripher Nerv Syst. 2011;16(3):237–42.

    Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Rose KJ, Raymond J, Refshauge K, North KN, Burns J. Serial night casting increases ankle dorsiflexion range in children and young adults with Charcot-Marie-tooth disease: a randomised trial. J Physiother. 2010;56(2):113–9.

    Article  Google Scholar 

  24. 24.

    Burns J, Ouvrier R, Yiu E, Joseph P, Kornberg A, Fahey M, et al. Ascorbic acid for Charcot–Marie–tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol. 2009;8(6):537–44.

    Article  CAS  Google Scholar 

  25. 25.

    Burns J, Ryan M, Ouvrier R. Evolution of foot and ankle manifestations in children with CMT1A. Muscle Nerve. 2009;39(2):158–66.

    Article  Google Scholar 

  26. 26.

    Newman CJ, Walsh M, O'Sullivan R, Jenkinson A, Bennett D, Lynch B, et al. The characteristics of gait in Charcot-Marie-tooth disease types I and II. Gait Posture. 2007;26(1):120–7.

    Article  Google Scholar 

  27. 27.

    Fowler EG, Staudt LA, Heberer KR, Sienko SE, Buckon CE, Bagley AM, et al. Longitudinal community walking activity in Duchenne muscular dystrophy. Muscle Nerve. 2018;57(3):401–6.

    Article  Google Scholar 

  28. 28.

    Goudriaan M, Van den Hauwe M, Dekeerle J, Verhelst L, Molenaers G, Goemans N, et al. Gait deviations in Duchenne muscular dystrophy-part 1. A systematic review. Gait Posture. 2018;62:247–61.

    Article  Google Scholar 

  29. 29.

    Victor RG, Sweeney HL, Finkel R, McDonald CM, Byrne B, Eagle M, et al. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. Neurology. 2017;89(17):1811–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Alfano LN, Miller NF, Berry KM, Yin H, Rolf KE, Flanigan KM, et al. The 100-meter timed test: normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Neuromuscul Disord. 2017;27(5):452–7.

    Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Ropars J, Lempereur M, Vuillerot C, Tiffreau V, Peudenier S, Cuisset J-M, et al. Muscle activation during gait in children with Duchenne muscular dystrophy. PLoS One. 2016;11(9):e0161938.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Davidson ZE, Ryan MM, Kornberg AJ, Walker KZ, Truby H. Strong correlation between the 6-minute walk test and Accelerometry functional outcomes in boys with Duchenne muscular dystrophy. J Child Neurol. 2015;30(3):357–63.

    Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Montes J, Garber CE, Kramer SS, Montgomery MJ, Dunaway S, Kamil-Rosenberg S, et al. A randomized, controlled clinical trial of exercise in patients with spinal muscular atrophy: methods and baseline characteristics. J Neuromuscul Dis. 2014;1(2):151–61.

    Article  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Pane M, Mazzone ES, Sivo S, Fanelli L, De Sanctis R, D'Amico A, et al. The 6 minute walk test and performance of upper limb in ambulant Duchenne muscular dystrophy boys. PLoS Curr. 2014;6.

  35. 35.

    Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S, et al. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS One. 2013;8(1):e52512.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arrieta A, et al. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve. 2013;48(1):55–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, de Bie E, et al. The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: Longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr. 2013; 07/08/13. Available from:

  38. 38.

    McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve. 2013;48(3):357–68.

    Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve. 2013;48(3):343–56.

    Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Bello L, Piva L, Barp A, Taglia A, Picillo E, Vasco G, et al. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology. 2012;79(2):159–62.

    Article  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Doglio L, Pavan E, Pernigotti I, Petralia P, Frigo C, Minetti C. Early signs of gait deviation in Duchenne muscular dystrophy. Eur J Phys Rehabil Med. 2011;47(4):587–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Mazzone E, Vasco G, Sormani MP, Torrente Y, Berardinelli A, Messina S, et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology. 2011;77(3):250–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Mazzone E, Martinelli D, Berardinelli A, Messina S, D'Amico A, Vasco G, et al. North star ambulatory assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2010;20(11):712–6.

    Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41(4):500–10.

    Article  PubMed  PubMed Central  Google Scholar 

  45. 45.

    D'Angelo MG, Berti M, Piccinini L, Romei M, Guglieri M, Bonato S, et al. Gait pattern in Duchenne muscular dystrophy. Gait Posture. 2009;29(1):36–41.

    Article  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Skura CL, Fowler EG, Wetzel GT, Graves M, Spencer MJ. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology. 2008;70(2):137–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Beenakker EAC, Fock JM, Van Tol MJ, Maurits NM, Koopman HM, Brouwer WOF, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. JAMA Neurology. 2005;62(1):128–32.

    Google Scholar 

  48. 48.

    Bartels B, Habets LE, Stam M, Wadman RI, Wijngaarde CA, Schoenmakers MAGC, et al. Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests. BMC Neurol. 2019;19(1):21.

    Article  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Montes J, Dunaway S, Garber CE, Chiriboga CA, De Vivo DC, Rao AK. Leg muscle function and fatigue during walking in spinal muscular atrophy type 3. Muscle Nerve. 2014;50(1):34–9.

    Article  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Dunaway S, Montes J, Garber CE, Carr B, Kramer SS, Kamil-Rosenberg S, et al. Performance of the timed "up & go" test in spinal muscular atrophy. Muscle Nerve. 2014;50(2):273–7.

    Article  Google Scholar 

  51. 51.

    Mazzone E, Bianco F, Main M, van den Hauwe M, Ash M, de Vries R, et al. Six minute walk test in type III spinal muscular atrophy: a 12month longitudinal study. Neuromuscul Disord. 2013;23(8):624–8.

    Article  CAS  Google Scholar 

  52. 52.

    Montes J, McDermott MP, Martens WB, Dunaway S, Glanzman AM, Riley S, et al. Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology. 2010;74(10):833–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. 53.

    Hayes HA, Dibella D, Crockett R, Dixon M, Butterfield RJ, Johnson NE. Stepping activity in children with congenital Myotonic dystrophy. Pediatr Phys Ther. 2018;30(4):335–9.

    Article  Google Scholar 

  54. 54.

    Johnson NE, Butterfield R, Berggren K, Hung M, Chen W, DiBella D, et al. Disease burden and functional outcomes in congenital myotonic dystrophy: a cross-sectional study. Neurology. 2016;87(2):160–7.

    Article  PubMed  PubMed Central  Google Scholar 

  55. 55.

    Eichinger K, Heatwole C, Heininger S, Stinson N, Matichak Stock C, Grosmann C, et al. Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2017;55(3):333–7.

    Article  PubMed  PubMed Central  Google Scholar 

  56. 56.

    McIntosh PT, Case LE, Chan JM, Austin SL, Kishnani P. Characterization of gait in late onset Pompe disease. Mol Genet Metab. 2015;116(3):152–6.

    Article  CAS  Google Scholar 

  57. 57.

    Meilleur KG, Jain MS, Hynan LS, Shieh CY, Kim E, Waite M, et al. Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies. Neuromuscul Disord. 2015;25(1):43–54.

    Article  Google Scholar 

  58. 58.

    Witherspoon JW, Vasavada R, Logaraj RH, Waite M, Collins J, Shieh C, et al. Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: is the 2-minute walk test an effective alternative to a 6-minute walk test? Eur J Paediatr Neurol. 2019;23(1):165–70.

    Article  CAS  Google Scholar 

  59. 59.

    Kaya P, Alemdaroglu I, Yilmaz O, Karaduman A, Topaloglu H. Effect of muscle weakness distribution on balance in neuromuscular disease. Pediatr Int. 2015;57(1):92–7.

    Article  Google Scholar 

  60. 60.

    Montes J, Blumenschine M, Dunaway S, Alter AS, Engelstad K, Rao AK, et al. Weakness and fatigue in diverse neuromuscular diseases. J Child Neurol. 2013;28(10):1277–83.

    Article  Google Scholar 

  61. 61.

    Holtebekk ME, Berntsen S, Rasmussen M, Jahnsen RB. Physical activity and motor function in children and adolescents with neuromuscular disorders. Pediatr Phys Ther. 2013;25(4):415–20.

    Article  Google Scholar 

  62. 62.

    Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in duchenne dystrophy. I. the design of the protocol. Muscle Nerve. 1981;4(3):186–97.

    Article  CAS  Google Scholar 

  63. 63.

    Pereira AC, Ribeiro MG, de Queiroz Campos Araújo AP, APdQC A. Timed motor function tests capacity in healthy children. Arch Dis Child. 2016;101(2):147–51.

    Article  Google Scholar 

  64. 64.

    Statement ATS. Guidelines for the six-minute walk test. Am J Resp Crit Care Med. 2002;166(1):111–7.

    Article  Google Scholar 

  65. 65.

    Bruininks RH, Bruininks BD. Bruininks-Oseretsky test of motor proficiency. 2nd ed. Minneapolis: Pearson; 2005.

    Google Scholar 

  66. 66.

    Podsiadlo D, Richardson S. The timed "up & go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.

    Article  CAS  Google Scholar 

  67. 67.

    Graham HK, Harvey A, Rodda J, Nattrass GR, Pirpiris M. The functional mobility scale (FMS). J Pediatr Orthop. 2004;24(5):514–20.

    Article  Google Scholar 

  68. 68.

    Graham RC, Hughes RAC. Clinimetric properties of a walking scale in peripheral neuropathy. J Neurol Neurosurg Psychiatry. 2006;77(8):977–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne natural history study. Neurology. 2015;85(12):1048–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Hof AL. Scaling gait data to body size. Gait Posture. 1996;4(3):222–3.

    Article  Google Scholar 

  71. 71.

    Stansfield BW, Hillman SJ, Hazlewood ME, Lawson AM, Mann AM, Loudon IR, et al. Normalisation of gait data in children. Gait Posture. 2003;17(1):81–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Lythgo N, Wilson C, Galea M. Basic gait and symmetry measures for primary school-aged children and young adults whilst walking barefoot and with shoes. Gait Posture. 2009;30(4):502–6.

    Article  PubMed  PubMed Central  Google Scholar 

  73. 73.

    Ng SS, Yu PC, To FP, Chung JS, Cheung TH. Effect of walkway length and turning direction on the distance covered in the 6-minute walk test among adults over 50 years of age: a cross-sectional study. Physiotherapy. 2013;99(1):63–70.

    Article  PubMed  PubMed Central  Google Scholar 

  74. 74.

    Beenakker EAC, Maurits NM, Fock JM, Brouwer OF, van der Hoeven JH. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Eur J Paediatr Neurol. 2005;9(6):387–93.

    Article  PubMed  PubMed Central  Google Scholar 

  75. 75.

    Mayhew JE, Florence JM, Mayhew TP. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve. 2007;35:36–42.

  76. 76.

    Burns J, Ouvrier R, Estilow T, Shy R, Laurá M, Pallant JF, et al. Validation of the Charcot–Marie–tooth disease pediatric scale as an outcome measure of disability. Ann Neurol. 2012;71(5):642–52.

    Article  PubMed  PubMed Central  Google Scholar 

  77. 77.

    Gan SM, Tung LC, Tang YH, Wang CH. Psychometric properties of functional balance assessment in children with cerebral palsy. Neurorehab Neural Re. 2008;22(6):745–53.

    Article  Google Scholar 

  78. 78.

    Carey H, Martin K, Combs-Miller S, Heathcock JC. Reliability and responsiveness of the timed up and go test in children with cerebral palsy. Pediatr Phys Ther. 2016;28(4):401–8.

    Article  PubMed  PubMed Central  Google Scholar 

  79. 79.

    Holland A, O'Connor RJ, Thompson AJ, Playford ED, Hobart JC. Talking the talk on walking the walk: a 12-item generic walking scale suitable for neurological conditions? J Neurol. 2006;253(12):1594–602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


The authors would like to thank the wider neuromuscular clinical and research community who contribute to a rich resource of publicly available knowledge in a field of rare diseases.



Author information




RK concept, review of the literature, drafted manuscript; KC – review of literature and reviewed draft manuscript; JM – reviewed draft manuscript; KP – concept and reviewed draft manuscript. All authors contributed to the writing and approved the final manuscript.

Corresponding author

Correspondence to Rachel A. Kennedy.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1.

Search strategy for narrative review “Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease”.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kennedy, R.A., Carroll, K., McGinley, J.L. et al. Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease. J Foot Ankle Res 13, 10 (2020).

Download citation


  • Neuromuscular disease
  • Duchenne muscular dystrophy
  • Spinal muscular atrophy
  • Charcot-Marie-tooth disease
  • Myopathy
  • Weakness
  • Paediatric
  • Gait
  • Functional ambulation
  • Assessment